Last updated on December 2019

Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC After Failure of Immune Checkpoint Inhibitor


Find a site near you

Start Over

CHU Montpellier

Montpellier, France
1.85miles
  Connect »